Search Results - Kenneth B. Gordon

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Biologic Sequence for the Treatment of Psoriatic Arthritis Following Nonresponse: A Narrative Review by Nicole D. Boswell, Alexa Ries, Kenneth B. Gordon, Shikha Singla

    Published in Dermatology and Therapy (2025-07-01)
    Get full text
    Article


  2. 2

    Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis by April W. Armstrong, Peter Foley, Yan Liu, Megan Miller, Rachel E. Teneralli, Anthony Bewley, Kenneth B. Gordon, Kim A. Papp, Chenglong Han

    Published in Dermatology and Therapy (2024-08-01)
    Get full text
    Article


  3. 3

    Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review by Andrew Blauvelt, Richard G. Langley, Kenneth B. Gordon, Jonathan I. Silverberg, Kilian Eyerich, Morten O. A. Sommer, Jakob Felding, Richard B. Warren

    Published in Dermatology and Therapy (2023-11-01)
    Get full text
    Article


  4. 4

    Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions by Kenneth B. Gordon, Yayoi Tada, Milan J. Anadkat, Siew Eng Choon, Boni Elewski, Jonathan N. Barker, Arash Mostaghimi, Kilian Eyerich, Ming Tang, Thomas Haeufel, Christian Thoma, Diamant Thaçi

    Published in Dermatology and Therapy (2025-02-01)
    Get full text
    Article


  5. 5

    Correction: Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions by Kenneth B. Gordon, Yayoi Tada, Milan J. Anadkat, Siew Eng Choon, Boni Elewski, Jonathan N. Barker, Arash Mostaghimi, Kilian Eyerich, Ming Tang, Thomas Haeufel, Christian Thoma, Diamant Thaçi

    Published in Dermatology and Therapy (2025-04-01)
    Get full text
    Article


  6. 6

    Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials by Kenneth B. Gordon, Andrew Blauvelt, Hervé Bachelez, Laura C. Coates, Filip E. Van den Bosch, Blair Kaplan, Willem Koetse, Doug G. Ashley, Ralph Lippe, Ranjeeta Sinvhal, Kim A. Papp

    Published in Dermatology and Therapy (2024-08-01)
    Get full text
    Article


  7. 7

    Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials by April W. Armstrong, Matthias Augustin, Jennifer L. Beaumont, Tan P. Pham, Stacie Hudgens, Kenneth B. Gordon, Joe Zhuo, Brandon Becker, Yichen Zhong, Renata M. Kisa, Subhashis Banerjee, Kim A. Papp

    Published in Dermatology and Therapy (2025-03-01)
    Get full text
    Article


  8. 8

    Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials by April W. Armstrong, Matthias Augustin, Jennifer L. Beaumont, Tan P. Pham, Stacie Hudgens, Kenneth B. Gordon, Joe Zhuo, Brandon Becker, Yichen Zhong, Renata M. Kisa, Subhashis Banerjee, Kim A. Papp

    Published in Dermatology and Therapy (2024-07-01)
    Get full text
    Article


Search Tools: